Last updated on March 2019

Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF)


Brief description of study

This is a multicenter, randomized (1:1; oral treprostinil to placebo), double-blind, placebo-controlled study in subjects with World Health Organization (WHO) Group 2 pulmonary hypertension (PH) associated with heart failure with preserved ejection fraction (HFpEF). Once randomized, subjects will take the initial dose of study drug at the study site on the day of randomization. Subjects will return to the study site for visits scheduled at Weeks 6, 12, 18, and 24. The treatment phase of the study will last approximately 24 weeks.

Clinical Study Identifier: NCT03037580

Find a site near you

Start Over

AnMed Health Pulmonary and Sleep Medicine

Anderson, SC United States
9.42miles
  Connect »

VitaLink Research - Anderson

Anderson, SC United States
9.42miles
  Connect »